Gregory Verdine

Biography

Gregory L. Verdine is the Erving Professor of Chemistry at Harvard University, with appointments in the Departments of Stem Cell & Regenerative Biology, Chemistry & Chemical Biology, and Molecular and Cellular Biology. He has pioneered the invention of completely new drug modalities capable of intervening in disease processes that were previously considered beyond therapeutic reach. He has also made major contributions to the understanding of innate systems in human cells that prevent the accumulation of cancer-causing mutations. Verdine holds a PhD in Chemistry from Columbia University and completed an NIH Postdoctoral Fellowship in molecular genetics at M.I.T. and Harvard Medical School. He founded a number of successful biotech companies, including Enanta Pharmaceuticals (NASDAQ: ENTA), Gloucester Pharmaceuticals (acquired by Celgene), Tokai Therapeutics (NASDAQ: TKAI) Eleven Bio (NASDAQ: EBIO), WAVE Life Sciences, Warp Drive Bio, Aileron Therapeutics, and FOG Pharmaceuticals. He also co-founded and is presently a Director of the non-profit Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy, which together are catalyzing the establishment of a biotechnology cluster in Gloucester, Massachusetts. Verdine has worked in life science investing as a Special Advisor to the Texas Pacific Group and a Venture Partner at AppleTree Ventures, and he is currently a Venture Partner at Third Rock Ventures. He serves on the Board of Scientific Advisors of the National Cancer Institute and the Board of Scientific Counselors of Memorial Sloan Kettering Cancer Center.

Research Interest

 Pharmaceuticals Sciences